文献速递肝病

非肝硬化成人α-1抗胰蛋白酶缺乏症的临床与组织学特征

Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.
PubMed 文献 · J Hepatol · 2018-08-21

研究前瞻性纳入94例经典基因型PI*ZZ的α-1抗胰蛋白酶缺乏症成人,评估肝纤维化患病率及危险因素。临床显著肝纤维化(F≥2)患病率为35.1%,代谢综合征与纤维化相关(OR 14.2),瞬时弹性成像检测F≥2的AUC为0.70。

要点

  • 94例PI*ZZ成人中临床显著肝纤维化(F≥2)患病率为35.1%。
  • 代谢综合征与临床显著纤维化相关(OR 14.2;95%CI 3.7-55;p<0.001)。
  • 瞬时弹性成像检测F≥2纤维化的AUC为0.70(95%CI 0.58-0.82)。

核心结论

  • 超过三分之一的无症状及肺部受累的PI*ZZ α-1抗胰蛋白酶缺乏症成人存在显著的潜在肝纤维化。
  • 肝纤维化风险在存在代谢综合征、肝细胞内AAT蓄积及基线活检门管区炎症时增加。
  • 结果支持该遗传病肝病可能源于肝细胞AAT蓄积所致「毒性获得功能」的假说。

研究设计与样本

  • 前瞻性研究,从北美招募94例经典基因型PI*ZZ的α-1抗胰蛋白酶缺乏症成人。
  • 进行肝功能转氨酶及合成功能标志物检测、瞬时弹性成像和肝活检。

主要发现

  • 临床显著肝纤维化(F≥2)患病率为35.1%。
  • F≥2组的丙氨酸氨基转移酶、天冬氨酸氨基转移酶和γ-谷氨酰转移酶值高于非F≥2组。
  • 代谢综合征与临床显著纤维化相关(OR 14.2;95%CI 3.7-55;p<0.001)。
  • 肝细胞内蓄积的异常AAT、门管区炎症及肝细胞变性均与临床显著纤维化相关。
  • 瞬时弹性成像检测F≥2纤维化的准确性一般,AUC为0.70(95%CI 0.58-0.82)。

关键数值与推荐

  • 临床显著肝纤维化定义为F≥2,患病率35.1%。
  • 代谢综合征与纤维化关联的OR为14.2(95%CI 3.7-55;p<0.001)。
  • 瞬时弹性成像检测F≥2纤维化的AUC为0.70(95%CI 0.58-0.82)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Alpha-1 antitrypsin deficiency (AATD) is an uncommonly recognized cause of liver disease in adults, with descriptions of its natural history limited to case series and patient-reported data from disease registries. Liver pathology is limited to selected patients or unavailable. Therefore, we aimed to determine the prevalence and severity of liver fibrosis in an adult AATD population who were not known to have cirrhosis, while defining risk factors for fibrosis and testing non-invasive markers of disease. METHODS: A total of 94 adults with classic genotype 'PI*ZZ' AATD were recruited from North America and prospectively enrolled in the study. Liver aminotransferases and markers of synthetic function, transient elastography, and liver biopsy were performed. RESULTS: The prevalence of clinically significant liver fibrosis (F ≥ 2) was 35.1%. Alanine aminotransferase, aspartate aminotransferase and gamma-glutamyltransferase values were higher in the F ≥ 2 group. Metabolic syndrome was associated with the presence of clinically significant fibrosis (OR 14.2; 95% CI 3.7-55; p <0.001). Additionally, the presence of accumulated abnormal AAT in hepatocytes, portal inflammation, and hepatocellular degeneration were associated with clinically significant fibrosis. The accuracy of transient elastography to detect F ≥ 2 fibrosis was fair, with an AUC of 0.70 (95% CI 0.58-0.82). CONCLUSIONS: Over one-third of asymptomatic and lung affected adults with 'PI*ZZ' AATD have significant underlying liver fibrosis. Liver biopsies demonstrated variable amounts of accumulated Z AAT. The risk of liver fibrosis increases in the presence of metabolic syndrome, accumulation of AAT in hepatocytes, and portal inflammation on baseline biopsy. The results support the hypothesis that liver disease in this genetic condition may be related to a "toxic gain of function" from accumulation of AAT in hepatocytes. LAY SUMMARY: Individuals diagnosed with classic alpha-1 antitrypsin deficiency (ZZ) are at risk of liver injury and scarring, because of the accumulation of abnormal alpha-1 antitrypsin in the liver. A liver biopsy in ZZ individuals can demonstrate the accumulation of alpha-1 antitrypsin within the liver and identify if any associated liver scarring is present. Indviduals with large amounts of alpha-1 antitrypsin on biopsy may be at risk of liver injury and fibrosis. Additional common medical conditions of diabetes, obesity, high cholesterol, and hypertension (known as metabolic syndrome) are associated with a greater degree of liver injury. CLINICAL TRIAL NUMBER: clinicaltrials.gov NCT01810458.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Clark VC, Marek G, Liu C, et al. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. J Hepatol. 2018. PMID: 30138687. doi:10.1016/j.jhep.2018.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。